Induction of CCL2 by siMAML1 through upregulation of TweakR in melanoma cells

Biochemical and Biophysical Research Communications

Volumn 372, Issue 4, 2008, Pages 629-633

  Kang, Shijun ^a   Yang, Chunlan ^b   Luo, Rongcheng ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b Department of Medicine   (China)

Author keywords

CCL2; Melanoma; Notch; siMAML1; TweakR

Indexed keywords

CHEMOATTRACTANT; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT; MASTERMIND LIKE PROTEIN 1; MESSENGER RNA; NOTCH RECEPTOR; PROTEIN HEY1; REPRESSOR PROTEIN; SMALL INTERFERING RNA; TWEAK RECEPTOR;

ARTICLE; CANCER CELL; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWNSTREAM PROCESSING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; MELANOMA; MICROENVIRONMENT; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; UPREGULATION;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CCL2; DNA-BINDING PROTEINS; GENE EXPRESSION; HUMANS; MELANOMA; MONOCYTES; NUCLEAR PROTEINS; PROTEIN BIOSYNTHESIS; RECEPTORS, NOTCH; RECEPTORS, TUMOR NECROSIS FACTOR; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; UP-REGULATION;

EID: 45449096453     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.05.079     Document Type: Article

References (34)

1. Pawelec G., Zeuthen J., and Kiessling R. Escape from host-antitumor immunity. Crit. Rev. Oncog. 8 (1997) 111-141
2. Pardoll D. Does the immune system see tumors as foreign or self?. Annu. Rev. Immunol. 21 (2003) 807-839
3. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
4. Burdelya L., Kujawski M., Niu G., Zhong B., Wang T., Zhang S., Kortylewski M., Shain K., Kay H., Djeu J., Dalton W., Pardoll D., Wei S., and Yu H. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J. Immunol. 174 (2005) 3925-3931
5. Wu L., and Griffin J.D. Modulation of Notch signaling by mastermind-like (MAML) transcriptional co-activators and their involvement in tumorigenesis. Semin. Cancer Biol. 14 (2004) 348-356
6. Hansson E.M., Lendahl U., and Chapman G. Notch signaling in development and disease. Semin. Cancer Biol. 14 (2004) 320-328
7. Larsson C., Lardelli M., White I., and Lendahl U. The human NOTCH1, 2, and 3 genes are located at chromosome positions 9q34, 1p13-p11, and 19p13.2-p13.1 in regions of neoplasia-associated translocation. Genomics 24 (1994) 253-258
8. Radtke F., and Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor?. Nat. Rev. Cancer 3 (2003) 756-767
9. Nickoloff B.J., Osborne B.A., and Miele L. Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene 22 (2003) 6598-6608
10. Koch U., and Radtke F. Notch and cancer: a double-edged sword. Cell Mol. Life Sci. (2007)
11. Nickoloff B.J., Qin J.Z., Chaturvedi V., Denning M.F., Bonish B., and Miele L. Jagged-1 mediated activation of notch signaling induces complete maturation of human keratinocytes through NF-kappaB and PPARgamma. Cell Death Differ. 9 (2002) 842-855
12. Curry C.L., Reed L.L., Golde T.E., Miele L., Nickoloff B.J., and Foreman K.E. Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene 24 (2005) 6333-6344
13. Konishi J., Kawaguchi K.S., Vo H., Haruki N., Gonzalez A., Carbone D.P., and Dang T.P. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res. 67 (2007) 8051-8057
14. Wiley S.R., and Winkles J.A. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev. 14 (2003) 241-249
15. Vince J.E., and Silke J. TWEAK shall inherit the earth. Cell Death Differ. 13 (2006) 1842-1844
16. Burkly L.C., Michaelson J.S., Hahm K., Jakubowski A., and Zheng T.S. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine 40 (2007) 1-16
17. Winkles J.A., Tran N.L., and Berens M.E. TWEAK and Fn14: new molecular targets for cancer therapy?. Cancer Lett. 235 (2006) 11-17
18. Negus R.P., Stamp G.W., Hadley J., and Balkwill F.R. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am. J. Pathol. 150 (1997) 1723-1734
19. Balkwill F. Cancer and the chemokine network. Nat. Rev. Cancer 4 (2004) 540-550
20. Kang S., Luo R., Smicun Y., Fishman D.A., and Meng Y. Selective induction of cyclooxygenase-2 plays a role in lysophosphatidic acid regulated Fas ligand cell surface presentation. FEBS Lett. 580 (2006) 443-449
21. Ando T., Ichikawa J., Wako M., Hatsushika K., Watanabe Y., Sakuma M., Tasaka K., Ogawa H., Hamada Y., Yagita H., and Nakao A. TWEAK/Fn14 interaction regulates RANTES production, BMP-2-induced differentiation, and RANKL expression in mouse osteoblastic MC3T3-E1 cells. Arthritis Res. Ther. 8 (2006) R146
22. Zhao Y., Katzman R.B., Delmolino L.M., Bhat I., Zhang Y., Gurumurthy C.B., Germaniuk-Kurowska A., Reddi H.V., Solomon A., Zeng M.S., Kung A., Ma H., Gao Q., Dimri G., Stanculescu A., Miele L., Wu L., Griffin J.D., Wazer D.E., Band H., and Band V. The notch regulator MAML1 interacts with p53 and functions as a coactivator. J. Biol. Chem. 282 (2007) 11969-11981
23. Yu H., Kortylewski M., and Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7 (2007) 41-51
24. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., and Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3 (2002) 991-998
25. Osborne B.A., and Kee B.L. Lymphoid development: it's not 'all Greek to us' any more. Nat. Immunol. 6 (2005) 119-123
26. Spaulding C., Reschly E.J., Zagort D.E., Yashiro-Ohtani Y., Beverly L.J., Capobianco A., Pear W.S., and Kee B.L. Notch1 co-opts lymphoid enhancer factor 1 for survival of murine T-cell lymphomas. Blood 110 (2007) 2650-2658
27. Chicheportiche Y., Bourdon P.R., Xu H., Hsu Y.M., Scott H., Hession C., Garcia I., and Browning J.L. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J. Biol. Chem. 272 (1997) 32401-32410
28. Maecker H., Varfolomeev E., Kischkel F., Lawrence D., LeBlanc H., Lee W., Hurst S., Danilenko D., Li J., Filvaroff E., Yang B., Daniel D., and Ashkenazi A. TWEAK attenuates the transition from innate to adaptive immunity. Cell 123 (2005) 931-944
29. Campbell S., Michaelson J., Burkly L., and Putterman C. The role of TWEAK/Fn14 in the pathogenesis of inflammation and systemic autoimmunity. Front. Biosci. 9 (2004) 2273-2284
30. Desplat-Jego S., Creidy R., Varriale S., Allaire N., Luo Y., Bernard D., Hahm K., Burkly L., and Boucraut J. Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis. Clin. Immunol. 117 (2005) 15-23
31. Nakayama M., Ishidoh K., Kojima Y., Harada N., Kominami E., Okumura K., and Yagita H. Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J. Immunol. 170 (2003) 341-348
32. Ho D.H., Vu H., Brown S.A., Donohue P.J., Hanscom H.N., and Winkles J.A. Soluble tumor necrosis factor-like weak inducer of apoptosis overexpression in HEK293 cells promotes tumor growth and angiogenesis in athymic nude mice. Cancer Res. 64 (2004) 8968-8972
33. Chicheportiche Y., Chicheportiche R., Sizing I., Thompson J., Benjamin C.B., Ambrose C., and Dayer J.M. Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies. Arthritis Res. 4 (2002) 126-133
34. Jin L., Nakao A., Nakayama M., Yamaguchi N., Kojima Y., Nakano N., Tsuboi R., Okumura K., Yagita H., and Ogawa H. Induction of RANTES by TWEAK/Fn14 interaction in human keratinocytes. J. Invest. Dermatol. 122 (2004) 1175-1179